Dtic-Dome Articles
New MM drug would do better in USA
26 January 2009
Seattle Genetics highlights Ab-drug conjugate programs
3 November 2008
Genasense Ph III trial progressing on target
13 October 2008
B-MS' ipilimumab doubles one-year survival of advanced melanoma patients
22 September 2008
Genta will complete AGENDA enrollment
22 September 2008
Genta updates of Genasense Ph III progress
30 June 2008
Stock Commentary - New York week to June 2, 2008
9 June 2008
Medarex/B-MS delay
5 May 2008
AFSSAPS gives OK to Ph III Genasense trial
22 October 2007
Genta enrolls first patients in Ph III Genasense trial
3 September 2007
Genta's Genasense gets second thumbs down from CHMP
30 July 2007
Genasense MAA rejected by CHMP
7 May 2007
Genta's shares climb 14% on Genasense news
30 April 2007
Genta to initiate new Ph III of Genasense
23 April 2007
Vical initiates Ph III trial of Allovectin-7
22 January 2007
Medarex' ipilimumab gets fast-track status
18 December 2006
Nexavar fails in Ph III melanoma study
11 December 2006
Genta unveils long-term Genasense trial data
16 October 2006
Viragen's Multiferon approved in Sweden
27 February 2006
Genasense confirms LDH role in melanoma
13 February 2006
EMEA accepts Genta's MA for Genasense
6 February 2006
Genta files Letter of Intent for Genasense MAA
11 July 2005
Bayer/Onyx initiate PH III sorafenib trial
23 May 2005
Vical completes SPA for Allovectin-7
21 February 2005
Viragen files Multiferon in Sweden for new use
14 February 2005
Promising new data for Viragen's Multiferon
11 October 2004
Positive Phase III data for Aventis/Genta's Genasense in melanoma
22 September 2003
MedImmune initiates two Ph II trials for Vitaxin
15 September 2003
Tokyo pharma stocks - week to April 8
15 April 2002
Genta's G3139 moves into Ph III for melanoma
21 July 2000
S-P's Temodal, efficacy in melanoma
27 January 2000
Genta's antisense drug to be fast-tracked
29 October 1999
Genta's antisense for cancer in Phase II
28 January 1999
Genta Starts PhI/IIA G3139 Study
25 June 1998
ANTI-ESTROGENS FOR MELANOMA?
7 September 1992
Showing 1-39 of 39 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
